We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study

MedXY Editorial Team•Sep 13, 2026•Hematology-Oncology
bệnh WilmsLymph node samplingpediatric oncologyイベントフリー生存期間overall survival

Highlight

– Lymph node (LN) positivity negatively impacts event-free survival (EFS) in stage I to III favorable histology Wilms tumor (FHWT).
– The total number of lymph nodes sampled is associated with overall survival (OS) in LN-negative patients.
– Neither the number of positive lymph nodes nor lymph node density predicts survival outcomes in LN-positive stage III patients.
– Findings emphasize the urgent need for standardized lymph node sampling protocols in FHWT surgical staging.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaA phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.Sep 6, 2026Genetic Risk and Ibrutinib Treatment Outcomes in Early-Stage CLL: Insights from the GCLLSG CLL12 TrialThe GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.Sep 1, 2026Epstein-Barr Virus Reactivation and PTLD in Pediatric Haploidentical HSCT: Incidence, Risks, and Clinical OutcomesThis study analyzes EBV infection and PTLD incidence in pediatric haploidentical HSCT, identifying prior CAR-T therapy, CMV viremia, and TBI conditioning as significant risk factors, with implications for enhanced monitoring and preemptiveAug 28, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients
Aug 26, 2026
Long-Term Risk of Second Primary Malignancies in Pediatric and Young Adult Differentiated Thyroid Cancer Survivors: A Four-Decade Real-World StudyPediatric and young adult survivors of differentiated thyroid cancer face a significant long-term risk of second primary malignancies, especially with radioactive iodine treatment, highlighting the need for extended surveillance and tailoreAug 17, 2026
Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I TrialThe COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progressionAug 13, 2026